Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
CDK4/6 inhibitor
DRUG CLASS:
CDK4/6 inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
palbociclib (222)
abemaciclib (80)
ribociclib (62)
dalpiciclib (11)
trilaciclib (3)
PRT3645 (3)
bireociclib (2)
HX301 (2)
CS3002 (1)
GLR2007 (1)
tibremciclib (1)
FCN-437 (1)
G1T38 (1)
ETH-155008 (0)
FLX925 (0)
HS-10342 (0)
SPH4336 (0)
SRX3177 (0)
TY-302 (0)
Undisclosed CDK4/6 inhibitor (0)
BPI-1178 (0)
palbociclib (222)
abemaciclib (80)
ribociclib (62)
dalpiciclib (11)
trilaciclib (3)
PRT3645 (3)
bireociclib (2)
HX301 (2)
CS3002 (1)
GLR2007 (1)
tibremciclib (1)
FCN-437 (1)
G1T38 (1)
ETH-155008 (0)
FLX925 (0)
HS-10342 (0)
SPH4336 (0)
SRX3177 (0)
TY-302 (0)
Undisclosed CDK4/6 inhibitor (0)
BPI-1178 (0)
›
Associations
(386)
News
Trials
VERI cancer hierarchy
Reset Filters
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
palbociclib
Sensitive: A1 - Approval
palbociclib
Sensitive
:
A1
palbociclib
Sensitive: A1 - Approval
palbociclib
Sensitive
:
A1
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
ribociclib
Sensitive: A1 - Approval
ribociclib
Sensitive
:
A1
ribociclib
Sensitive: A1 - Approval
ribociclib
Sensitive
:
A1
HR positive
HER2 Negative Breast Cancer
HR positive
HER2 Negative Breast Cancer
abemaciclib
Sensitive: A1 - Approval
abemaciclib
Sensitive
:
A1
abemaciclib
Sensitive: A1 - Approval
abemaciclib
Sensitive
:
A1
HR positive
Hormone Receptor Positive Breast Cancer
HR positive
Hormone Receptor Positive Breast Cancer
ribociclib
Sensitive: A1 - Approval
ribociclib
Sensitive
:
A1
ribociclib
Sensitive: A1 - Approval
ribociclib
Sensitive
:
A1
PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
PIK3CA mutation + HR positive
HER2 Negative Breast Cancer
palbociclib + inavolisib
Sensitive: A1 - Approval
palbociclib + inavolisib
Sensitive
:
A1
palbociclib + inavolisib
Sensitive: A1 - Approval
palbociclib + inavolisib
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + abemaciclib
Sensitive: A2 - Guideline
trastuzumab + abemaciclib
Sensitive
:
A2
trastuzumab + abemaciclib
Sensitive: A2 - Guideline
trastuzumab + abemaciclib
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
ribociclib
Sensitive: A2 - Guideline
ribociclib
Sensitive
:
A2
ribociclib
Sensitive: A2 - Guideline
ribociclib
Sensitive
:
A2
ER positive
Endometrial Cancer
ER positive
Endometrial Cancer
ribociclib
Sensitive: A2 - Guideline
ribociclib
Sensitive
:
A2
ribociclib
Sensitive: A2 - Guideline
ribociclib
Sensitive
:
A2
ER positive
Endometrial Cancer
ER positive
Endometrial Cancer
abemaciclib
Sensitive: A2 - Guideline
abemaciclib
Sensitive
:
A2
abemaciclib
Sensitive: A2 - Guideline
abemaciclib
Sensitive
:
A2
No biomarker
Breast Cancer
No biomarker
Breast Cancer
abemaciclib
Sensitive: A2 - Guideline
abemaciclib
Sensitive
:
A2
abemaciclib
Sensitive: A2 - Guideline
abemaciclib
Sensitive
:
A2
No biomarker
Liposarcoma
No biomarker
Liposarcoma
palbociclib
Sensitive: A2 - Guideline
palbociclib
Sensitive
:
A2
palbociclib
Sensitive: A2 - Guideline
palbociclib
Sensitive
:
A2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
palbociclib
Sensitive: A2 - Guideline
palbociclib
Sensitive
:
A2
palbociclib
Sensitive: A2 - Guideline
palbociclib
Sensitive
:
A2
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.